Abstract
Our knowledge on diagnosis and treatment of osteoporosis has steadily increased during the past decade. Several guidelines on treatment of osteoporosis are now available. Although there is heterogeneity in these recommendations, there are several common suggestions found. Case finding is advocated in all; however, it is generally acknowledged that further research is necessary to evaluate the effectiveness of case-finding strategies. Dual-energy x-ray absorptiometry is considered the gold standard for diagnosis of osteoporosis. The use of the T score is different for diagnostic purposes and for treatment decisions. Other bone measurement techniques are proposed as risk evaluation or as alternatives when dual-energy x-ray absorptiometry is not available. Bone markers are not considered for evaluation in clinical practice. Treatment options include general measures on lifestyle, fall prevention, calcium and vitamin D supplements, hormone therapy, raloxifene, and bisphosphonates. Consistent recommendations are found mostly for raloxifene in the prevention of vertebral fractures and for alendronate and risedronate in the prevention of vertebral and nonvertebral fractures, including hip fractures.
Similar content being viewed by others
References and Recommended Reading
Guyatt G: Evidence-based medicine in everyday practice. Cleve Clin J Med 1999, 66:461–464.
Woolf SH, Grol R, Hutchinson A, et al.: Clinical guidelines: potential benefits, limitations, and harms of clinical guidelines. BMJ 1999, 318:527–530.
Cranney A, Waldegger L, Graham I, et al.: Systematic assessment of the quality of osteoporosis guidelines. BMC Musculoskelet Disord 2002, 3:20.
Rossignol M, Moride Y, Perreault S, et al.: Recommendations for the prevention of osteoporosis and fragility fractures. International comparison and synthesis. Int J Technol Assess Health Care 2002, 18:597–610.
Kanis JA, Torgerson D, Cooper C: Comparison of the European and USA practice guidelines for osteoporosis. Trends Endocrinol Metab 2000, 11:28–32.
Kanis JA, Gluer CC: An update on the diagnosis and assessment of osteoporosis with densitometry. Committee of Scientific Advisors, International Osteoporosis Foundation. Osteoporos Int 2000, 11:192–202. This paper includes a thorough review on measurement technology.
Osteoporosis: review of the evidence for prevention, diagnosis and treatment and cost-effectiveness analysis. Executive summary. Osteoporos Int 1998, 8(Suppl 4):S3–6.
Royal College of Physicians: Osteoporosis: clinical guidelines for prevention and treatment. http://www.rcplondon.ac.uk/ pubs/wp_osteo_update.htm. Accessed July 12, 2003. This site gives extensive detailed documentation of treatment studies.
Hodgson SF, Watts NB, Bilezikian JP, et al.: American Association of Clinical Endocrinologists 2001 Medical Guidelines for Clinical Practice for the Prevention and Management of Postmenopausal Osteoporosis. Endocr Pract 2001, 7:293–312.
Hart W: The new CBO-guideline ‘osteoporosis’ is a broadly supported standard for clinical practice. Ned Tijdschr Geneeskd 2002, 146:1352–1354.
Brown JP, Josse RG: 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. Can Med Assoc J 2002, 167(Suppl 10):S1–34. This report contains extensive and detailed analyses.
Diagnosis and treatment of osteoporosis. Institute for Clinical Systems Improvement (ICSI). www.icsi.org/knowledge. Accessed July 12, 2003.
North American Menopause Society. www.guidelines.gov/ VIEWS. Accessed July 12, 2003.
National Institutes of Health, USA. Osteoporosis prevention, diagnosis, and therapy. NIH Consensus Statement 2000, 17:1–45. A concise report was given at this meeting of experts.
Cranney A, Guyatt G, Griffith L, et al.: Meta-analyses of therapies for postmenopausal osteoporosis. IX: summary of metaanalyses of therapies for postmenopausal osteoporosis. Endocr Rev 2002, 4:570–578. This paper gives an extensive meta-analysis of available evidence on drug treatment for fracture prevention.
Nelson HD, Helfand M, Woolf SH, Allan JD: Screening for postmenopausal osteoporosis: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002, 137:529–541.
Khan AA, Brown J, Faulkner K, et al.: Standards and guidelines for performing central dual x-ray densitometry from the Canadian panel of International Society for Clinical Densitometry. J Clin Densitom 2002, 5:247–257.
Delmas PD, Eastell R, Garnero P, et al.: The use of biochemical markers of bone turnover in osteoporosis. Committee of Scientific Advisors of the International Osteoporosis Foundation. Osteoporos Int 2000, 11(Suppl 6):S2–17.
Recommendations for the prevention and treatment of glucocorticoid -induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocoritcoid-Induced Osteoporosis. Arthritis Rheum 2001, 44:1496–1503.
Glucocorticoid-induced osteoporosis. http://www.rcplondon. ac.uk/pubs/books/glucocorticoid/index.asp. Accessed July 12, 2003. This web site contains extensive reports and detailed reviews of publications on several aspects of GIOP.
Kanis JA, Black D, Cooper C, et al.: A new approach to the development of assessment guidelines for osteoporosis. Osteoporos Int 2002, 13:527–536.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Geusens, P.P.M.M. Review of guidelines for testing and treatment of osteoporosis. Curr Osteoporos Rep 1, 59–65 (2003). https://doi.org/10.1007/s11914-003-0010-y
Issue Date:
DOI: https://doi.org/10.1007/s11914-003-0010-y